Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era

por Isaac E. Kim, Thomas L. Jang, Sinae Kim, David Y. Lee, Daniel D. Kim, Eric A. Singer, Saum Ghodoussipour, Mark N. Stein, Monish Aron, Marc A. Dall’Era, Isaac Yi Kim
Publicado 2021

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

por Karen A. Autio, Emmanuel S. Antonarakis, Tina M. Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan, Michael J. Morris, Susan F. Slovin, Elisabeth I. Heath, Scott T. Tagawa, Dana E. Rathkopf, Matthew I. Milowsky, Michael R. Harrison, Tomasz M. Beer, Arjun V. Balar, Andrew J. Armstrong, Daniel J. George, Channing J. Paller, Arlyn Apollo, Daniel C. Danila, Julie N. Graff, Luke Nordquist, Erica S. Dayan Cohn, Kin Tse, Nicole A. Schreiber, Glenn Heller, Howard I. Scher
Publicado 2021